TRACON Pharmaceuticals to Present at Upcoming Investment Conferences

SAN DIEGO, May 31, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the following investor conferences in June:

Jefferies 2016 Healthcare Conference3:00 pm EDT on Tuesday, June 7, 2016, in New York, NY

JMP Securities Life Sciences Conference12:00 pm EDT on Wednesday, June 22, 2016, at The St. Regis in New York, NY

To access a live webcast of the presentations, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.  A replay of the webcasts will be available on the website for 30 days following the events.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:   
Casey Logan    
Chief Business Officer   
(858) 550‐0780 ext. 236  
[email protected]  

Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
[email protected]

Source: TRACON Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• How travelers can support wild animals rather than exploit them
• Music Industry Community Founder Christy DiNapoli Introduces AI-Powered Operating System for Independent Artists & Musicians
• Ermenegildo Zegna Group Reports First Half 2026 Revenues of €987 Million With Profit at €28 Million and Adjusted EBIT at €74 Million